Old Web
English
Sign In
Acemap
>
authorDetail
>
Garvin Warner
Garvin Warner
Alnylam Pharmaceuticals
Internal medicine
Biology
Endocrinology
Small interfering RNA
RNA interference
5
Papers
49
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis
2019
Nucleic Acid Therapeutics
Jessica E. Sutherland
Julia Hettinger
Amy Chan
Jason A Gilbert
Garvin Warner
Wendell P Davis
Show All
Source
Cite
Save
Citations (6)
The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies:
2018
Toxicologic Pathology
Maja M. Janas
Carole E. Harbison
Victoria K. Perry
Brenda Carito
Jessica Sutherland
Akshay Vaishnaw
Natalie D. Keirstead
Garvin Warner
Show All
Source
Cite
Save
Citations (26)
A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results
2015
Blood
Anita Hill
Jorg Taubel
Jim Bush
Anna Borodovsky
Noriyuki Kawahata
Helen Mclean
Christine Powell
Prasoon Chaturvedi
Garvin Warner
Pushkal Garg
Benny Sorensen
Show All
Source
Cite
Save
Citations (15)
Reproductive performance and early postnatal development in interleukin (IL)-13-deficient mice.
2012
Birth Defects Research Part B-developmental and Reproductive Toxicology
David J. Wright
Karissa Adkins
Daniel R. Minck
Steven Bailey
Garvin Warner
Michael W. Leach
Show All
Source
Cite
Save
Citations (2)
Assessment of immunization against recombinant human bone morphogenetic protein-2 (dibotermin alpha) on reproduction and development in rabbits.
2011
Birth Defects Research Part B-developmental and Reproductive Toxicology
David J. Wright
Daniel R. Minck
John Adam Nowak
Garvin Warner
Mark Cukierski
Show All
Source
Cite
Save
Citations (0)
1